NASDAQ:RLMD Relmada Therapeutics (RLMD) Stock Price, News & Analysis $0.32 +0.04 (+13.48%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Relmada Therapeutics Stock (NASDAQ:RLMD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Relmada Therapeutics alerts:Sign Up Key Stats Today's Range$0.27▼$0.3350-Day Range$0.25▼$0.7452-Week Range$0.24▼$4.47Volume2.30 million shsAverage Volume869,245 shsMarket Capitalization$10.70 millionP/E RatioN/ADividend YieldN/APrice Target$4.25Consensus RatingHold Company OverviewRelmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.Read More… Relmada Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks85th Percentile Overall ScoreRLMD MarketRank™: Relmada Therapeutics scored higher than 85% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingRelmada Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageRelmada Therapeutics has received no research coverage in the past 90 days.Read more about Relmada Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Relmada Therapeutics are expected to grow in the coming year, from ($2.73) to ($0.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Relmada Therapeutics is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Relmada Therapeutics is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRelmada Therapeutics has a P/B Ratio of 0.11. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Relmada Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.70% of the float of Relmada Therapeutics has been sold short.Short Interest Ratio / Days to CoverRelmada Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Relmada Therapeutics has recently decreased by 12.96%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRelmada Therapeutics does not currently pay a dividend.Dividend GrowthRelmada Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.45 Percentage of Shares Shorted5.70% of the float of Relmada Therapeutics has been sold short.Short Interest Ratio / Days to CoverRelmada Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Relmada Therapeutics has recently decreased by 12.96%, indicating that investor sentiment is improving significantly. News and Social Media1.8 / 5News Sentiment0.27 News SentimentRelmada Therapeutics has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Relmada Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for RLMD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Relmada Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Relmada Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders20.70% of the stock of Relmada Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions45.24% of the stock of Relmada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Relmada Therapeutics' insider trading history. Receive RLMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Relmada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RLMD Stock News HeadlinesRelmada Therapeutics Presents NDV-01 Data at AUA2025 Conference for High-Risk Non-Muscle Invasive Bladder CancerApril 28 at 8:20 PM | nasdaq.comRelmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025April 28 at 1:38 PM | globenewswire.comURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. April 30, 2025 | Golden Portfolio (Ad)Relmada Therapeutics to hold a virtual meetingApril 27 at 11:59 PM | markets.businessinsider.comUPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025April 27 at 9:00 AM | globenewswire.comRelmada Therapeutics to Host KOL Event on Phase 2 NDV-01 DataApril 24, 2025 | globenewswire.comUPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025April 14, 2025 | globenewswire.comRelmada Therapeutics To Present NDV-01 Data at AUA2025April 14, 2025 | globenewswire.comSee More Headlines RLMD Stock Analysis - Frequently Asked Questions How have RLMD shares performed this year? Relmada Therapeutics' stock was trading at $0.52 on January 1st, 2025. Since then, RLMD shares have decreased by 38.0% and is now trading at $0.3224. View the best growth stocks for 2025 here. How were Relmada Therapeutics' earnings last quarter? Relmada Therapeutics, Inc. (NASDAQ:RLMD) announced its quarterly earnings results on Thursday, March, 27th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.70) by $0.08. Read the conference call transcript. How do I buy shares of Relmada Therapeutics? Shares of RLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Relmada Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Relmada Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), ServiceNow (NOW), GE Aerospace (GE) and Adobe (ADBE). Company Calendar Last Earnings3/27/2025Today4/30/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RLMD CIK1553643 Webwww.relmada.com Phone(786) 629-1376FaxN/AEmployees10Year Founded2004Price Target and Rating Average Stock Price Target$4.25 High Stock Price Target$13.00 Low Stock Price Target$1.00 Potential Upside/Downside+1,232.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-98,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-129.80% Return on Assets-112.06% Debt Debt-to-Equity RatioN/A Current Ratio6.89 Quick Ratio6.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.84 per share Price / Book0.11Miscellaneous Outstanding Shares33,192,000Free Float24,743,000Market Cap$10.58 million OptionableOptionable Beta0.41 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:RLMD) was last updated on 4/30/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredTop performing AI play of the decade…? (The answer will shock you)You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relmada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.